Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.

NCT01571895 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT01571895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01571895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 2
Overall status
Terminated
Start date
February 20, 2012
Completion date
July 5, 2012
Enrollment
4 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bullous pemphigoid